How big is the veterinary orthobiologics market?

In 2027 the market for veterinary orthobiologics is valued at USD 931.3 million.

What is the anticipated CAGR of the veterinary orthobiologics industry?

Veterinary Orthobiologics Market size was valued at USD 870.7 million in 2026 and is anticipated to grow at a 8.27% CAGR from 2027 to 2036, crossing USD 1.93 billion by 2036.

How is regenerative medicine shaping clinical adoption in the veterinary orthobiologics market?

Advances in regenerative therapies such as platelet-rich plasma and stem cell applications are improving treatment outcomes for orthopedic injuries, encouraging earlier adoption in clinical practice and expanding use in specialty and referral veterinary settings.

How is pet insurance influencing access to advanced veterinary orthopedic biologic treatments?

Expanding pet insurance coverage reduces cost barriers, enabling veterinarians to position orthobiologic therapies as viable options. This increases treatment uptake in insured cases, improving conversion from diagnosis to intervention in orthopedic conditions.

Why is Platelet-rich Plasma (PRP) the leading product segment in the veterinary orthobiologics market?

PRP held a 41.55% share in 2026 because it integrates easily into routine veterinary orthopedic care, offering a familiar biologic treatment option without adding significant procedural complexity.

Why is the Canine segment growing the fastest in the veterinary orthobiologics market?

The Canine segment, with a 48.87% share in 2026, is also the fastest-growing due to high demand for orthopedic and mobility care and greater adoption of biologic therapies for recovery and long-term function.

Why does North America lead the veterinary orthobiologics market?

North America held a 45.82% market share in 2026, supported by advanced veterinary infrastructure, higher orthopedic procedure volumes, organized distribution networks, and broader adoption of regenerative treatments.

What is fueling veterinary orthobiologics market growth in Asia Pacific?

Asia Pacific is projected to expand at a 10.06% CAGR, driven by rising pet ownership, improving veterinary access, expanding clinic capabilities, and increasing demand for advanced musculoskeletal treatments.

Who are the major participants shaping the veterinary orthobiologics landscape?

Prominent players in the veterinary orthobiologics market include Zoetis Inc. (United States), Boehringer Ingelheim International GmbH (Germany), Arthrex, Inc. (United States), VetStem, Inc. (United States), Dechra Pharmaceuticals PLC (United Kingdom), Enovis Corporation (United States), Movora (United States), Ardent Animal Health LLC (United States), Enso Discoveries LLC (United States), T-Cyte Therapeutics, Inc. (United States).